<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001256687
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2019
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYROSA 20MG F.C.TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ROSUVASTATIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        67.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="OMAN PHARMACEUTICAL PRODUCTS" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            OMAN PHARMACEUTICAL PRODUCTS
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C10AA07 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;<strong>1) WHAT ZYROSA IS AND WHAT IT IS USED FOR </strong></p><p>Zyrosa belongs to a group of medicines called statins.</p><p><strong>You have been prescribed ZYROSA because: </strong></p><p>&bull; You have a high cholesterol level. This means you are at risk from a heart attack or stroke. Zyrosa is used in adults, adolescents and children 6 years or older to treat high cholesterol.</p><p>You have been advised to take a statin, because changing your diet and taking more exercise were not enough to correct your cholesterol levels. You should continue with your cholesterol-lowering diet and exercise while you are taking Zyrosa.</p><p>&nbsp;Or</p><p>&bull; You have other factors that increase your risk of having a heart attack, stroke or related health problems.</p><p>Heart attack, stroke and other problems can be caused by a disease called atherosclerosis. Atherosclerosis is due to build up of fatty deposits in your arteries.</p><p><strong>Why is it important to keep taking ZYROSA? </strong></p><p>Zyrosa is used to correct the levels of fatty substances in the blood called lipids, the most common of which is cholesterol.</p><p>There are different types of cholesterol found in the blood &ndash; &lsquo;bad&rsquo; cholesterol (LDL-C) and &lsquo;good&rsquo; cholesterol (HDL-C).</p><p>&bull; Zyrosa can reduce the &lsquo;bad&rsquo; cholesterol and increase the &lsquo;good&rsquo; cholesterol.</p><p>&bull; It works by helping to block your body&rsquo;s production of &lsquo;bad&rsquo; cholesterol. It also improves your body&rsquo;s ability to remove it from your blood. &nbsp;</p><p>&nbsp;</p><p>For most people, high cholesterol does not affect the way they feel because it does not produce any symptoms. However, if it is left untreated, fatty deposits can build up in the walls of your blood vessels causing them to narrow.</p><p>Sometimes, these narrowed blood vessels can get blocked which can cut off the blood supply to the heart or brain leading to a heart attack or a stroke. By lowering your cholesterol levels, you can reduce your risk of having a heart attack, a stroke or related health problems.</p><p>You need to <strong>keep taking Zyrosa</strong>, even if it has got your cholesterol to the right level, because <strong>it prevents your cholesterol levels from creeping up again </strong>and causing build up of fatty deposits. However, you should stop if your doctor tells you to do so, or you have become pregnant.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Zyrosa: </strong></p><p>&bull; <strong>If you have ever had an allergic reaction to Zyrosa</strong><strong>,</strong> or to any of its ingredients.</p><p>&bull; <strong>If you are pregnant </strong>or breast-feeding. If you become pregnant while taking Zyrosa <strong>stop taking it immediately and tell your doctor</strong>. Women should avoid becoming pregnant while taking Zyrosa by using suitable contraception.</p><p>&bull; <strong>If you have liver disease. </strong></p><p>&bull; <strong>If you have severe kidney problems</strong>.</p><p>&bull; <strong>If you have repeated or unexplained muscle aches or pains</strong>.</p><p>&bull; <strong>If you take a drug called ciclosporin </strong>(used, for example, after organ transplants)</p><p>If any of the above applies to you (or you are in doubt), <strong>please go back and see your doctor</strong>.</p><p><strong>In addition, do not take Zyrosa 40 mg (the highest dose): </strong></p><p>&bull; <strong>If you have moderate kidney problems </strong>(if in doubt, please ask your doctor).</p><p>&bull; <strong>If your thyroid gland </strong>is not working properly.</p><p>&bull; <strong>If you have had any repeated or unexplained muscle aches or pains</strong>, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines.</p><p>&bull; <strong>If you regularly drink large amounts of alcohol. </strong></p><p>&bull; <strong>If you are of Asian origin </strong>(Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull; <strong>If you take other medicines called fibrates </strong>to lower your cholesterol.</p><p>If any of the above applies to you (or you are in doubt), <strong>please go back and see your doctor</strong>.</p><p><strong>WARNINGS AND PRECAUTIONS:</strong></p><p>Talk to your doctor or pharmacist before taking Zyrosa.</p><p>&bull; <strong>If you have problems with your kidneys</strong>.</p><p>&bull; <strong>If you have problems with your liver</strong>.</p><p><strong>If you have had repeated or unexplained muscle aches or pains</strong>, a personal or family history of muscle problems, or a previous history of muscle problems when taking other cholesterol-lowering medicines. Tell your doctor immediately if you have unexplained muscle aches or pains especially if you feel unwell or have a fever. Also tell your doctor or pharmacist if you have a muscle weakness that is constant.</p><p>&bull; <strong>If you regularly drink large amounts of alcohol. </strong></p><p>&bull; <strong>If your thyroid gland </strong>is not working properly.</p><p>&bull; <strong>If you take other medicines called fibrates </strong>to lower your cholesterol. Please read this leaflet carefully, even if you have taken other medicines for high cholesterol before.</p><p>&bull; <strong>If you take medicines used to treat the HIV infection </strong>e.g. ritonavir with lopinavir and/or atazanavir, please see <strong>Other medicines and Zyrosa</strong>.</p><p>If you are taking or have taken in the last 7 days a medicine called fusidic acid (a<br />medicine for bacterial infection), orally or by injection. The combination of Fusidic acid and <strong>Zyrosa</strong>. can lead to serious muscle problems (rhabdomyolysis), please see &ldquo;Other medicines and zyrosa&rdquo;.</p><p>&bull; If you are over 70 (as your doctor needs to choose the right start dose of Zyrosa to suit you)<br />&bull; If you have severe respiratory failure.<br />&bull; If you are of Asian origin &ndash; that is Japanese, Chinese, Filipino, Vietnamese, Korean and Indian. Your doctor needs to choose the right start dose of Zyrosa to suit you.</p><p><br />If any of the above applies to you (or if you are not sure):<br />&bull; Do not take Zyrosa 40 mg (the highest dose) and check with your doctor or<strong> pharmacist before you actually start taking any dose of </strong>Zyrosa.</p><p><br />In a small number of people, statins can affect the liver. This is identified by a simple test<br />which looks for increased levels of liver enzymes in the blood. For this reason, your doctor<br />will usually carry out this blood test (liver function test) before and during treatment withZyrosa.</p><p><br />While you are on this medicine your doctor will monitor you closely if you have diabetes or are at risk of developing diabetes. You are likely to be at risk of developing diabetes if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure.</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>&bull; <strong>If the patient is under 6 years old: </strong>Zyrosa should not be given to children younger than 6 years.</p><p>&bull; <strong>If the patient is below 18 years of age</strong>: The Zyrosa 40 mg tablet is not suitable for use in children and adolescents below 18 years of age.</p><p>&nbsp;</p><p><strong>Other medicines and Zyrosa </strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>Tell your doctor if you are taking any of the following: ciclosporin (used for example, after organ transplants), warfarin or clopidogrel (or any other drug used for thinning the blood), fibrates (such as gemfibrozil, fenofibrate) or any other medicine used to lower cholesterol (such as ezetimibe), indigestion remedies (used to neutralise acid in your stomach), erythromycin (an antibiotic), fusidic acid (an antibiotic &ndash; please see Warnings and precautions), an oral contraceptive (the pill), hormone replacement therapy or anti-viral medications such as ritonavir with lopinavir and/or atazanavir or simeprevir (used to treat infections, including HIV or hepatitis C infection &ndash; please see Warnings and precautions). The effects of these medicines could be changed by Zyrosa or they could change the effects of Zyrosa.</p><p>If you need to take oral Fusidic acid to treat a bacterial infection you will need to<br />temporarily stop using this medicine. Your doctor will tell you when it is safe to restart<br /><strong>Zyrosa. Taking Zyrosa with Fusidic acid may rarely lead to muscle weakness,</strong><br />tenderness or pain (rhabdomyolysis). See more information regarding rhabdomyolysis<br />in Section 4.</p><p><strong>Pregnancy and breast-feeding </strong></p><p><strong>Do not take Zyrosa </strong>if you are pregnant or breast-feeding. If you become pregnant while taking Zyrosa <strong>stop taking it immediately </strong>and tell your doctor. Women should avoid becoming pregnant while taking Zyrosa by using suitable contraception.</p><p>Ask your doctor or pharmacist for advice before taking any medicine.</p><p><strong>Driving and using machines </strong></p><p>Most people can drive a car and operate machinery while using Zyrosa &ndash; it will not affect their ability. However, some people feel dizzy during treatment with Zyrosa. If you feel dizzy, consult your doctor before attempting to drive or use machines. &nbsp;</p><p><strong>Zyrosa</strong><strong> contains lactose</strong>.</p><p>If you have been told by your doctor that you have an intolerance to some sugars (lactose or milk sugar), contact your doctor before taking Zyrosa.</p><p>For a full list of ingredients please see <strong>Contents of the pack and other information.</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3) HOW TO TAKE ZYROSA </strong></p><p>Always take this medicine as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Usual doses in adults </strong></p><p><strong>If you are taking Zyrosa for high cholesterol: </strong></p><p><strong>Starting dose </strong></p><p>Your treatment with Zyrosa must start with the <strong>5 mg or the 10 mg dose</strong>, even if you have taken a higher dose of a different statin before. The choice of your start dose will depend upon:</p><p>&bull; Your cholesterol level.</p><p>&bull; The level of risk you have of experiencing a heart attack or stroke.</p><p>&bull; Whether you have a factor that may make you more sensitive to possible side effects.</p><p>Please check with your doctor or pharmacist which start dose of Zyrosa will best suit you.</p><p>Your doctor may decide to give you the lowest dose (5 mg) if:</p><p>You are of <strong>Asian origin </strong>(Japanese, Chinese, Filipino, Vietnamese, Korean and Indian).</p><p>&bull; You are <strong>over 70 years </strong>of age.</p><p>&bull; You have moderate kidney problems.</p><p>&bull; You are at risk of muscle aches and pains (myopathy).</p><p><strong>Increasing the dose and maximum daily dose </strong></p><p>Your doctor may decide to increase your dose. This is so that you are taking the amount of Zyrosa that is right for you. If you started with a 5 mg dose, your doctor may decide to double this to 10 mg, then 20 mg and then 40 mg if necessary. If you started on 10 mg, your doctor may decide to double this to 20 mg and then 40 mg if necessary. There will be a gap of four weeks between every dose adjustment.</p><p>The maximum daily dose of Zyrosa is 40 mg. It is only for patients with high cholesterol levels and a high risk of heart attacks or stroke whose cholesterol levels are not lowered enough with 20 mg.</p><p><strong>If you are taking Zyrosa to reduce your risk of having a heart attack, stroke or related health problems: </strong></p><p>The recommended dose is 20 mg daily. However, your doctor may decide to use a lower dose if you have any of the factors mentioned above.</p><p><strong>Use in children and adolescents aged 6-17 years </strong></p><p>The dose range in children and adolescents aged 6 to 17 years is 5 to 20 mg once daily. The usual start dose is 5 mg. Your doctor may increase your dose to find the right amount of Zyrosa for you. The maximum daily dose of Zyrosa is 10 mg or 20mg for children aged 6 to 17 years depending on your underlying condition being treated. Take your dose once a day. Zyrosa <strong>40 mg </strong>tablet should <strong>not </strong>be used by children.</p><p><strong>&nbsp;</strong></p><p><strong>Taking your tablets </strong></p><p>Swallow each tablet whole with a drink of water.</p><p><strong>Take Zyrosa once daily</strong>. You can take it at any time of the day with or without food.</p><p>Try to take your tablet at the same time every day to help you to remember it.</p><p><strong>Regular cholesterol checks </strong></p><p>It is important to go back to your doctor for regular cholesterol checks, to make sure your cholesterol has reached and is staying at the correct level.</p><p>Your doctor may decide to increase your dose so that you are taking the amount of Zyrosa that is right for you.</p><p><strong>If you take more Zyrosa than you should </strong></p><p>Contact your doctor or nearest hospital for advice.</p><p>If you go into hospital or receive treatment for another condition, tell the medical staff that you&rsquo;re taking Zyrosa.</p><p><strong>If you forget to take ZYROSA </strong></p><p>Don&rsquo;t worry, just take your next scheduled dose at the correct time. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking ZYROSA </strong></p><p>Talk to your doctor if you want to stop taking Zyrosa. Your cholesterol levels might increase again if you stop taking Zyrosa.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify"><strong>4) POSSIBLE SIDE EFFECTS </strong></p><p style="text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p style="text-align:justify">It is important that you are aware of what these side effects may be. They are usually mild and disappear after a short time.</p><p style="text-align:justify"><strong>Stop taking Zyrosa and seek medical help immediately </strong>if you have any of the following allergic reactions:</p><p style="text-align:justify">&bull; Difficulty in breathing, with or without swelling of the face, lips, tongue and/or throat</p><p style="text-align:justify">&bull; Swelling of the face, lips, tongue and/or throat, which may cause difficulty in swallowing</p><p style="text-align:justify">&bull; Severe itching of the skin (with raised lumps).</p><p style="text-align:justify"><strong>Also, stop taking Zyrosa and talk to your doctor immediately if you have any unusual aches or pains </strong>in your muscles which go on for longer than you might expect. Muscle symptoms are more common in children and adolescents than in adults. As with other statins, a very small number of people have experienced unpleasant muscle effects and rarely these have gone on to become a potentially life threatening muscle damage known as <em>rhabdomyolysis</em>.</p><p style="text-align:justify"><strong>&nbsp;</strong></p><p style="text-align:justify"><strong>Common possible side effects (these may affect between 1 in 10 and 1 in 100 patients):</strong></p><p style="text-align:justify">&bull; Headache</p><p style="text-align:justify">&bull; Stomach pain</p><p style="text-align:justify">&bull; Constipation</p><p style="text-align:justify">&bull; Feeling sick</p><p style="text-align:justify">&bull; Muscle pain</p><p style="text-align:justify">&bull; Feeling weak</p><p style="text-align:justify">&bull; Dizziness</p><p style="text-align:justify">&bull; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your Zyrosa tablets (only Zyrosa 40 mg)</p><p style="text-align:justify">&bull; Diabetes. This is more likely if you have high levels of sugars and fats in your blood, are overweight and have high blood pressure. Your doctor will monitor you while you are taking this medicine.</p><p style="text-align:justify"><strong>Uncommon possible side effects (these may affect between 1 in 100 and 1 in 1,000 patients): </strong></p><p style="text-align:justify">&bull; Rash, itching or other skin reactions</p><p style="text-align:justify">&bull; An increase in the amount of protein in the urine - this usually returns to normal on its own without having to stop taking your Zyrosa tablets (only Zyrosa 10 mg and 20 mg).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Rare possible side effects (these may affect between 1 in 1,000 and 1 in 10,000 patients): </strong></p><p style="text-align:justify">&middot;&nbsp;&nbsp; Severe allergic reaction &ndash; signs include swelling of the face, lips, tongue and/or throat, difficulty in swallowing and breathing, a severe itching of the skin (with raised lumps). <strong>If you think you are having an allergic reaction, then stop taking Zyrosa </strong>and seek medical help immediately</p><p style="text-align:justify">&middot;&nbsp;&nbsp; Muscle damage in adults &ndash; as a precaution, <strong>stop taking Zyrosa and talk to your doctor immediately if you have any unusual aches or pains </strong>in your muscles which go on for longer than expected</p><p style="text-align:justify">&middot;&nbsp;&nbsp; A severe stomach pain (inflamed pancreas)</p><p style="text-align:justify">&middot;&nbsp;&nbsp; Increase in liver enzymes in the blood</p><p style="text-align:justify">&middot;&nbsp;&nbsp; Bleeding or bruising more easily than normal due to low level of blood platelets.</p><p style="text-align:justify"><strong>Very rare possible side effects (these may affect less than 1 in 10,000 patients): </strong></p><p style="text-align:justify">&bull; Jaundice (yellowing of the skin and eyes)</p><p style="text-align:justify">&bull; Hepatitis (an inflamed liver)</p><p style="text-align:justify">&bull; Traces of blood in your urine</p><p style="text-align:justify">&bull; Damage to the nerves of your legs and arms (such as numbness)</p><p style="text-align:justify">&bull; Joint pain</p><p style="text-align:justify">&bull; Memory loss</p><p style="text-align:justify">&bull; Breast enlargement in men (gynaecomastia)</p><p style="text-align:justify"><strong>Side effects of unknown frequency may include: </strong></p><p style="text-align:justify">&bull; Diarrhoea (loose stools)</p><p style="text-align:justify">&bull; Stevens-Johnson syndrome (serious blistering condition of the skin, mouth, eyes and genitals)</p><p style="text-align:justify">&bull; Cough</p><p style="text-align:justify">&bull; Shortness of breath</p><p style="text-align:justify">&bull; Oedema (swelling)</p><p style="text-align:justify">&bull; Sleep disturbances, including insomnia and nightmares</p><p style="text-align:justify">&bull; Sexual difficulties</p><p style="text-align:justify">&bull; Depression</p><p style="text-align:justify">&bull; Breathing problems, including persistent cough and/or shortness of breath or fever</p><p style="text-align:justify">&bull; Tendon injury</p><p style="text-align:justify">&bull; Muscle weakness that is constant</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. HOW TO STORE ZYROSA</strong></p><p>Store below 30&ordm;C.</p><p>Protect from light and moisture</p><p>Keep out of reach of children.</p><p>&nbsp;&bull; Do not use this medicine after the expiry date which is stated on the box/blisters after EXP. The expiry date refers to the last day of the month.</p><p>&bull; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>6. CONTENTS OF THE PACK AND OTHER INFORMATION</strong></p><p>&nbsp;<strong>What </strong><strong>ZYROSA</strong><strong> contains: </strong></p><p>The active substance in Zyrosa is rosuvastatin. Zyrosa film-coated tablets contain rosuvastatin calcium equivalent to 10 mg, 20 mg or 40 mg of rosuvastatin. The other ingredients are: lactose monohydrate, microcrystalline cellulose, tribasic calcium phosphate, crospovidone, magnesium stearate, Opadry pink 02F84852 &amp; purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What ZYROSA looks like and contents of the pack 
Zyrosa tablets are supplied in Alu/Alu blister packs of 2 x 14’s tablets.
Zyrosa comes in three tablet strengths:
Pink round shaped film coated tablet, debossed with “R 40” on one side and plain on other side.
Pink round shaped film coated tablet, debossed with “R 20” on one side and plain on other side.
Pink round shaped film coated tablet, debossed with “R 10” on one side and plain on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Oman Pharmaceutical Products Co., L.L.C.</p><p>Salalah, Sultanate of Oman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last updated in October 2018
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>1) ما هو زيروسا وما هي استخداماته </strong></p><p dir="RTL">زيروسا ينتمي إلى مجموعة من الأدوية تسمى الستاتين.</p><p dir="RTL">لقد تم وصف زيروسا لك للأسباب التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أن يكون لديك ارتفاع في مستوى الكوليسترول. هذا يعني أنك في خطر من نوبة قلبية أو سكتة دماغية. يستخدم زيروسا في البالغين والمراهقين والأطفال 6 سنوات أو أكثر لعلاج ارتفاع الكوليسترول في الدم.</p><p dir="RTL">يتم نصحك بأخذ أدوية الستاتين، لأن تغيير النظام الغذائي الخاص بك، والقيام بالمزيد من التمارين ليست كافية لتصحيح مستويات الكولسترول لديك. يجب عليك الاستمرار مع النظام الغذائي الخاص بك لخفض الكولسترول وممارسة الرياضة وأنت تتناول زيروسا.</p><p dir="RTL">أو</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اذا كان لديك غيرها من العوامل التي قد تزيد من خطر الإصابة بنوبة قلبية والسكتة الدماغية أو المشاكل الصحية ذات الصلة.</p><p dir="RTL">النوبة القلبية والسكتة الدماغية وغيرها من المشاكل يمكن أن يكون سببها مرض يسمى تصلب الشرايين. ويرجع تصلب الشرايين.إلى تراكم الترسبات الدهنية في الشرايين.</p><p dir="RTL"><strong>لماذا من المهم أن تستمر في تناول زيروسا؟</strong></p><p dir="RTL">يستخدم زيروسا لتصحيح مستويات المواد الدهنية في الدم التي تسمى الدهون، والأكثر شيوعا منها هو الكولسترول.</p><p dir="RTL">وهناك أنواع مختلفة من الكوليسترول موجودة في الدم - الكوليسترول &#39;السيئ&#39; (LDL-C) و الكوليسترول &#39;الجيد&#39;(HDL-C).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيروسا يمكنها خفض الكولسترول &quot;السيئ&quot; وزيادة الكولسترول &quot;الجيد&quot;.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعمل عن طريق مساعدة جسمك في منع إنتاجه للكولسترول &quot;السيئ &quot;. كما أنها تحسن قدرة الجسم على إزالته من الدم.</p><p dir="RTL">بالنسبة لمعظم الناس، ارتفاع الكوليسترول في الدم لا يؤثر على الطريقة التي يشعرون بها لأنها لا تنتج أي أعراض. ومع ذلك، إذا تركت دون علاج، يمكن للرواسب دهنية أن تتراكم في جدران الأوعية الدموية مما يسبب لها تضييق.</p><p dir="RTL">في بعض الأحيان، هذه الأوعية الدموية الضيقة يمكن يحصل لها انسداد الذي يمكن أن يقلل من وصول الدم إلى القلب أو الدماغ مما يؤدي إلى نوبة قلبية أو سكتة دماغية. عن طريق خفض مستويات الكولسترول، يمكنك تقليل خطر الإصابة بنوبة قلبية أو سكتة دماغية أو مشاكل صحية ذات الصلة.</p><p dir="RTL">يجب <strong>المحافظة على تناول زيروسا</strong>، حتى لو وصلت مستويات الكولسترول إلى المستوى المطلوب، <strong>لأنه يمنع مستويات الكولسترول من أن ترتفع من جديد</strong> وتسبب تراكم الترسبات الدهنية. ومع ذلك، يجب أن تتوقف إذا طلب منك الطبيب للقيام بذلك، أو إذا كنتي قد أصبحتي حاملا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>2) ما تحتاج إلى معرفته قبل تناول زيروسا</strong></p><p dir="RTL"><strong>لا تتناول زيروسا:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك في أي وقت مضى الحساسية لزيروسا</strong>، أو الى أي من مكوناته.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتي حاملا</strong> أو تقومين بالرضاعة الطبيعية. إذا أصبحت حاملا في حين تتناولين زيروسا <strong>توقفي عن تناولها</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>&nbsp;على الفور وإخبري الطبيب بذلك</strong>. يجب على النساء تجنب الحمل أثناء تناول زيروسا باستخدام وسائل منع الحمل المناسبة.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كان لديك مرض الكبد.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كان لديك مشاكل شديدة في الكلى.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كان لديك &nbsp;قد آلام أو اوجاع متكررة أو غير المبررة في العضلات.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تأخذ دواء يسمى سيكلوسبورين</strong> (المستخدم، على سبيل المثال، بعد زرع الأعضاء)</p><p dir="RTL">إذا كان أي من ما سبق ينطبق عليك (أو كنت في شك)، <strong>يرجى العودة ومراجعة الطبيب</strong>.</p><p dir="RTL"><strong>وبالإضافة إلى ذلك، لا تتناول زيروسا</strong><strong> 40</strong><strong>ملجم (أعلى جرعة):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك مشاكل متوسطة&nbsp; في الكلى</strong> (إذا كنت في شك، يرجى الاستفسار من طبيبك).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>في حالة عدم عمل الغدة الدرقية </strong>لديك بشكل صحيح.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك أي آلام أو اوجاع متكررة أو غير مبررة في العضلات</strong> ، أو كان لديك سابقا او في تاريخ العائلة مشاكل في العضلات، أو حصل لديك &nbsp;سابقا مشاكل في العضلات عند أخذ أدوية أخرى لخفض الكولسترول.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت تشرب بانتظام كميات كبيرة من الكحول.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت من أصل آسيوي</strong> (اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تأخذ أدوية أخرى تدعى فايبريت</strong> لخفض الكولسترول.</p><p dir="RTL">إذا كان أي من ما سبق ينطبق عليك (أو كنت في شك)، <strong>يرجى العودة ومراجعة الطبيب</strong>.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">تحدث مع طبيبك أو الصيدلاني قبل تناول زيروسا.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كان لديك مشاكل مع الكليتين.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كان لديك مشاكل في الكبد.</strong></p><p dir="RTL">إذا كان لديك آلام أو أوجاع متكررة أو غير المبررة في العضلات ، أو كان لديك سابقا او في تاريخ العائلة مشاكل في العضلات، أو حصل لديك &nbsp;سابقا مشاكل في العضلات عند أخذ أدوية أخرى لخفض الكولسترول. أخبر طبيبك فورا إذا كان لديك آلام في العضلات أو آلام غير مبررة وخاصة إذا كنت تشعر بتوعك أو لديك حمى. كما أخبر طبيبك أو الصيدلي إذا كان لديك ضعف مستمر في العضلات.</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كنت تشرب بانتظام كميات كبيرة من الكحول.</strong></p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>في حال تعطل عمل الغدة الدرقية بشكل صحيح.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تأخذ أدوية أخرى تدعى فايبريت </strong>لخفض الكولسترول. يرجى قراءة هذه النشرة بعناية، حتى لو كنت قد تناولت أدوية أخرى لارتفاع الكوليسترول في الدم.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تأخذ الأدوية المستخدمة لعلاج العدوى بفيروس نقص المناعة البشرية</strong> على سبيل المثال ريتونافير مع وبينافير و / أو اتازنفير، الرجاء مراجعة <strong>الأدوية الأخرى و زيروسا</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت أكثر من 70 سنة</strong> (طبيبك يحتاج إلى اختيار الجرعة المبدئية من زيروسا التي تناسبك)</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا كان لديك فشل حاد في الجهاز التنفسي.</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت من أصل آسيوي</strong> - وهذا يقصد به اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية. الطبيب الخاص بك يحتاج إلى اختيار الجرعة الابتدائية من زيروسا التي تناسبك.</p><p dir="RTL">إذا كان أي من ما سبق ينطبق عليك (أو إذا لم تكن متأكدا):</p><p dir="RTL"><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>لا تتناول زيروسا</strong><strong> 40</strong><strong>ملجم (أعلى جرعة) وتحقق مع طبيبك أو الصيدلي قبل البدء فعليا في تناول أي جرعة من زيروسا.</strong></p><p dir="RTL">في عدد قليل من الناس، يمكن للستاتسن (الاودية المخفضة للكوليسترول)أن تؤثر على الكبد. يتم التعرف على ذلك من خلال اختبار بسيط يتحقق من زيادة مستويات أنزيمات الكبد في الدم. لهذا السبب، فإن الطبيب عادة ما يقوم بطلب عمل من هذا الاختبار للدم (اختبار وظيفة الكبد) قبل وأثناء العلاج مع زيروسا.</p><p dir="RTL">أثناء تناولك لهذا الدواء سيراقب الطبيب عن كثب لك إذا كنت مصابا بداء السكري أو المعرضين لخطر الإصابة بمرض السكري. من المحتمل أن تكون في خطر ظهور الاصابة بمرض السكر إذا كان لديك مستويات عالية من السكريات والدهون في الدم، ويعانون من زيادة الوزن وارتفاع ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان المريض تحت 6 سنوات من العمر:</strong> لا ينبغي أن يعطى زيروسا للأطفال الذين تقل أعمارهم عن 6 سنوات.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان المريض أقل من 18 سنة من العمر: </strong>إن زيروسا40 ملجم ليست مناسبة للاستخدام في الأطفال والمراهقين دون 18 سنة من العمر.</p><p dir="RTL"><strong>الأدوية الأخرى وزيروسا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد تناولت مؤخرا أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">أخبر طبيبك إذا كنت تأخذ أي من الادوية التالية: سيكلوسبورين (التي تستخدم على سبيل المثال، بعد زرع الأعضاء)، الوارفارين أو كلوبيدوقرل (أو أي نوع من الادوية الأخرى المستخدمة لمنع تجلط الدم)، فايبريتس (مثل جمفبروزيل، فينوفايبرات) أو أي دواء آخر المستخدم في خفض الكولسترول (مثل إزتيميب)، وعلاجات عسر الهضم (التي تستخدم لتحييد الحمض الموجود في المعدة)، الاريثروميسين (مضاد حيوي)، وحمض الفوسيديك (مضاد حيوي - يرجى الاطلاع على التحذيرات والاحتياطات)، و وسائل منع الحمل عن طريق الفم (حبوب منع الحمل)، العلاج بالهرمونات التعويضيةأو الأدوية المضادة للفيروسات مثل ريتونافير مع وبينافير و / أو اتازنفير أو سيمبريفير(التي تستخدم لعلاج الالتهابات، بما في ذلك فيروس نقص المناعة البشرية أو التهاب الكبد C - يرجى الاطلاع على التحذيرات والاحتياطات). فعالية هذه الأدوية يمكن ان يتغير مع زيروسا أو أنها يمكن أن تغير من فعالية زيروسا.</p><p dir="RTL">كنت بحاجة إلى تناول حمض الفيوسديك اسيد عن طريق الفم لعلاج عدوى بكتيرية ستحتاج إلى التوقف مؤقتًا عن استخدام هذا الدواء. سيخبرك طبيبك عندما يكون من الآمن مباشرة استخدام زيروسا قد يؤدي تناول زيروسا مع حمض فيوسديك اسيد إلى ضعف و &nbsp;ايلام أو ألم العضلات (انحلال الربيدات).للمزيد من المعلومات بشأن انحلال الربيدات في القسم 4.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>لا تأخذيزيروسا</strong> إذا كنت حاملا أو تقومين بالرضاعة الطبيعية. إذا أصبحت حاملا في حين كنت تتناولينزيروسا<strong>أوقفيتناولها على الفور</strong> وإخبري الطبيب بذلك. يجب على النساء تجنب الحمل أثناء تناول زيروسا باستخدام وسائل منع الحمل المناسبة.</p><p dir="RTL">إسأل طبيبك أو الصيدلي للحصول على المشورة قبل اتخاذ أي دواء.</p><p dir="RTL"><strong>القيادة واستخدام آلات</strong></p><p dir="RTL">معظم الناس يمكن أن يقود السيارة واستخدام الآلات أثناء تناولزيروسا - أنها لن تؤثر في قدرتهم. ومع ذلك، بعض الناس يشعرون بالدوار خلال فترة العلاج مع زيروسا. إذا كنت تشعر بالدوار، استشر طبيبك قبل محاولة قيادة السيارة أو استخدام الآلات.</p><p dir="RTL">زيروسا يحتوي على اللاكتوز.</p><p dir="RTL">إذا تمابلاغك من قبل طبيبك أن لديك التعصب لبعض السكريات (اللاكتوز أو سكر الحليب)، اتصل بطبيبك قبل تناولزيروسا.</p><p dir="RTL">للحصول على قائمة كاملة من المكونات لهذا المنتج يرجى الاطلاع على <strong>محتويات العبوة وغيرها من المعلومات</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">3<strong>) كيفية تناول زيروسا</strong></p><p dir="RTL">دائما تناول هذا الدواء كما قال لك طبيبك. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL"><strong>الجرعات المعتادة في البالغين</strong></p><p dir="RTL"><strong>إذا كنت تتناولزيروسا لارتفاع الكوليسترول في الدم:</strong></p><p dir="RTL"><strong>جرعة البدء</strong></p><p dir="RTL">العلاج بزيروسا يجب أن تبدأ مع 5 ملجم أو جرعة 10 ملجم، حتى لو كنت قد تناولت جرعة عالية من أدوية مختلفة من الستاتين من قبل. وسيكون اختيار جرعة البداية الخاصة بك يعتمد على:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى الكولسترول لديك.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستوى الخطر لديك من بنوبة قلبية أو سكتة دماغية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أحد العوامل التي قد تجعلك أكثر حساسية للآثار الجانبية المحتملة.</p><p dir="RTL">يرجى التحقق مع طبيبك أو الصيدلي ما هي جرعة البدء من زيروساالتي سوف تتناسبك.</p><p dir="RTL">طبيبك قد يقرر أن يعطيك أقل جرعة (5 ملجم) إذا:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنت من <strong>أصل آسيوي</strong> (اليابانية والصينية والفلبينية والفيتنامية والكورية والهندية).</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنت <strong>أكثر من 70 عاما</strong> من العمر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل متوسطة في الكلى.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أنت في خطر من الاصابة بآلام أو الاوجاع في العضلات (عضلي).</p><p dir="RTL"><strong>زيادة الجرعة والجرعة اليومية القصوى</strong></p><p dir="RTL">قد يقرر الطبيب زيادة الجرعة. وهذا هو الحال حتى تأخذ كمية زيروساالتى تناسبك. إذا كنت بدأت مع جرعة 5 ملجم، فإن طبيبك قد يقرر مضاعفتها إلى 10 ملجم، ثم 20 ملجم و ثم 40 ملجم إذا لزم الأمر. إذا بدأت في 10 ملجم، فإن طبيبك قد يقرر مضاعفتها إلى 20 ملجم و ثم 40 ملجم إذا لزم الأمر. سوف تكون هناك فجوة أربعة أسابيع بين كل تعديل الجرعة.</p><p dir="RTL">الجرعة اليومية القصوى من زيروسا هي 40 ملجم. تعطى فقط للمرضى الذين لديهم مستويات مرتفعة من الكولسترول زنسبة مرتفعة من مخاطر الإصابة بالأزمات القلبية أو السكتة الدماغية الذين لم يتم خفض مستويات الكوليسترول في الدم بما فيه الكفاية مع 20 ملجم.</p><p dir="RTL"><strong>إذا كنت تتناولزيروسا للحد من خطر الإصابة بنوبة قلبية والسكتة الدماغية أو المشاكل الصحية ذات الصلة:</strong></p><p dir="RTL">الجرعة الموصى بها هي 20 ملجم &nbsp;يوميا. ومع ذلك، قد يقرر الطبيب إلى استخدام أقل جرعة إذا كان لديك أي من العوامل المذكورة أعلاه.</p><p dir="RTL"><strong>الاستخدام في الأطفال والمراهقين الذين تتراوح أعمارهم بين 6-17 سنوات</strong></p><p dir="RTL">الجرعة المناسبة للأطفال والمراهقين الذين تتراوح أعمارهم بين 6 إلى 17 سنة هو 5 إلى 20 ملغ مرة واحدة يوميا.الجرعة البدء المعتادة هي 5 ملجم. طبيبك قد يزيد الجرعة إلى للعثور على الكمية المناسبة من زيروساالمناسبة لك.</p><p dir="RTL">&nbsp;الجرعة اليومية القصوى من زيروسا هي 10 ملجمأو 20 ملجم للأطفال الذين تتراوح أعمارهم بين 6 إلى 17 عامااعتمادا على حالتك الكامنة التي يتم علاجها. خذ الجرعة مرة واحدة في اليوم. لا ينبغي أن تستخدم زيروسا 40ملجم من قبل الأطفال.</p><p dir="RTL"><strong>تناولالأقراص الخاصة بك</strong></p><p dir="RTL">ابتلع كل قرص بأكمله مع شربة ماء.</p><p dir="RTL"><strong>تناولزيروسا مرة واحدة يوميا.</strong> يمكنك أن تتناولها في أي وقت من اليوم مع أو بدون الطعام.</p><p dir="RTL">حاول أن تتناول قرصك اليومي في نفس الوقت من كل يوم لمساعدتك على تذكرها.</p><p dir="RTL"><strong>فحوصات الكولسترول الاعتيادية</strong></p><p dir="RTL">ومن المهم أن العودة &nbsp;إلى الطبيب لاجراء فحوص الكولسترول الاعتيادية، للتأكد من مستويات الكولسترول وصلت واستقرت في المستوى الصحيح.</p><p dir="RTL">الطبيب قد يقرر زيادة الجرعة بحيث تأخذ الكمية المناسبة لك من زيروسا.</p><p dir="RTL"><strong>إذا كنت تتناول أكثر مما يجب من زيروسا</strong></p><p dir="RTL">اتصل بطبيبك أو أقرب مستشفى للحصول على المشورة.</p><p dir="RTL">إذا ذهبت إلى المستشفى أو تلقيت العلاج لحالة أخرى، أخبر الطاقم الطبي أنك تتناول زيروسا.</p><p dir="RTL"><strong>إذا كنت قد نسيت أن تتناولزيروسا</strong></p><p dir="RTL">لا تقلق، فقط تناول الجرعة القادمة المقررة في الوقت الصحيح. لا تأخذ جرعة مضاعفة لتعويض الجرعة المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول زيروسا</strong></p><p dir="RTL">تحدث مع طبيبك إذا كنت ترغب في التوقف عن تناول زيروسا. مستويات الكولسترول قد تزيد مرة أخرى إذا توقفت عن تناول زيروسا.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، إسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>4) الآثار الجانبية المحتملة</strong></p><p dir="RTL">مثل جميع الأدوية، يمكن لهذا الدواء يسبب آثارا جانبية، على الرغم من أن الجميع لا تظهر لديهم.</p><p dir="RTL">من المهم أن تكون على بينة من ما قد تكون هذه الآثار الجانبية. أنها عادة ما تكون خفيفة وتختفي بعد وقت قصير.</p><p dir="RTL"><strong>توقف عن تناول زيروسا وأطلب المساعدة الطبية على الفور</strong> إذا كان لديك أي من الحساسية التالية:</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس، مع أو من دون تورم في الوجه والشفتين واللسان و / أو الحلق</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والشفتين واللسان و / أو الحلق، والتي قد تسبب صعوبة في البلع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة شديدة في الجلد (مع كتل مرتفعة).</p><p dir="RTL"><strong>توقف أيضا، عن تناول زيروسا وتحدث الى الطبيب فورا إذا كان لديك أي آلام غير عادية أو</strong></p><p dir="RTL"><strong>&nbsp;اوجاع في العضلات</strong> الخاصة بك والتي تستمر لفترة أطول مما هو متوقع. أعراض العضلات هي أكثر شيوعا في الأطفال والمراهقين مقارنة بالبالغين. كما هو الحال مع العقاقير المخفضة للكوليسترول الأخرى، شهد عدد قليل جدا من الناس الآثار العضلات الغير مرغوبة، ونادرا ما قد تطورت إلى أن تصبح تلف العضلات مهدد للحياة المعروف باسم انحلال الربيدات.</p><p dir="RTL"><strong>الآثار الجانبية الشائعةالممكنة (وهذه قد تؤثر على ما بين 1 في 10 و 1 في 100 مريض):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع الراس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المعدة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالارجاع</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم العضلات</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دوخة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية البروتين في البول - وهذا عادة ما يعود إلى وضعه الطبيعي من تلقاء نفسه دون الحاجة إلى التوقف عن تناول أقراص زيروسا الخاص بك (فقط زيروسا 40 ملجم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;مرض السكري. هذا على الأرجح إذا كان لديك مستويات عالية من السكريات والدهون في الدم، وتعاني من زيادة الوزن وارتفاع ضغط الدم. طبيبك سوف يقوم بمراقبتك وأنت تأخذ هذا الدواء.</p><p dir="RTL"><strong>الآثار الجانبية الغير شائعة الممكنة (وهذه قد تؤثر على ما بين 1 في 100 و 1 في 1000 مريض):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، والحكة أو ردود فعل الجلد الأخرى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في كمية البروتين في البول - وهذا عادة ما يعود إلى وضعها الطبيعي من تلقاء نفسها دون الحاجة إلى التوقف عن تناول أقراص الكمبيوتر زيروسا (فقط زيروسا 5 ملجم، 10 ملجم و 20 ملجم).</p><p dir="RTL"><strong>الآثار الجانبية النادرة الممكنة (وهذه قد تؤثر على ما بين 1 في 1000 و 1 في 10000 مريض):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي شديد - وتشمل علامات تورم في الوجه والشفتين واللسان و / أو الحلق، وصعوبة في البلع والتنفس، وحكة شديدة في الجلد (مع كتل مرتفعة على الجلد). <strong>إذا كنت تعتقد أنك تعاني من الحساسية، توقف عن تناول زيروسا</strong> وأطلب المساعدة الطبية فورا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف العضلات في البالغين - كإجراء احترازي، <strong>توقف عن تناول زيروسا والتحدث الى الطبيب فورا إذا كان لديك أي آلام غير عادية أو أوجاع</strong> في العضلات&nbsp; والتي تستمر لفترة أطول مما كان متوقعا</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم شديد في المعدة (التهاب البنكرياس)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في انزيمات الكبد في الدم</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &bull; نزيف أو كدمات أسهل من المعتاد بسبب انخفاض مستوى الصفائح الدموية.</p><p dir="RTL"><strong>الآثار الجانبية النادرة جدا المحتملة (وهذه قد تؤثر على أقل من 1 في كل10000 مريض):</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اليرقان (اصفرار الجلد والعينين)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الكبد (تضخم الكبد الملتهب)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آثار دم في البول</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأضرار التي تلحق بأعصاب الساقين والذراعين (مثل التنميل)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الذاكرة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي لدى الرجال (تثدي)</p><p dir="RTL"><strong>الآثار الجانبية الغير معروفة الترددويمكن أن تشمل:</strong></p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال (براز رخو)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; متلازمة ستيفنز جونسون (خطيرة حالة ظهور تقرحات في الجلد والفم والعينين والأعضاء التناسلية)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سعال</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وذمة (تورم)</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطرابات النوم، بما في ذلك الأرق والكوابيس</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصعوبات الجنسية</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كآبة</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في التنفس، بما في ذلك السعال المستمر و / أو ضيق في التنفس أو الحمى</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إصابة الوتر</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات المستمر</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>5. كيفية تخزين زيروسا</strong></p><p dir="RTL">يحفظ في درجة حرارة &nbsp;أقل من 30 درجة مئوية .</p><p dir="RTL">يحفظ بعيدا عن الضوء والرطوبة</p><p dir="RTL">تبقي بعيدا عن متناول الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المنصوص عليه في العبوة الكرتونيةوشريط الاقراص</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعد EXP. تاريخ انتهاء الصلاحية يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدم. ومن شأن هذه التدابير أن تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>6. محتويات العبوة زمة وغيرها من المعلومات</strong></p><p dir="RTL"><strong>على ماذا يحتوي زيروسا:</strong></p><p>المادة الفعالة في زيروسا هي رسيوفاستاتين. زيروسا أقراص مغلفة بفيلم تحتوي على كالسيوم رسيوفاستاتين ما يعادل 5 ملجم، 10 ملجمو 20 ملجمأو 40 ملجممن رسيوفاستاتين. المكونات الأخرى هي: مونوهيدرات اللاكتوز، ميكروكريستالين السليلوز ، فوسفات الكالسيوم الثلاثية القاعدة، كروسبوفيدون، ستيرات المغنيسيوم، أوبدري الوردي 02F84852 والمياه النقية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>ما هو شكل ومحتويات عبوةزيروسا</strong></p><p dir="RTL" style="text-align:right">يتم توفير أقراص زيروسا في شريطألو / ألو &nbsp;عبوة من 2 &times; 14 قرص.</p><p dir="RTL" style="text-align:right">زيروسا يأتي في ثلاثة تراكيز:</p><p dir="RTL" style="text-align:right">قرص وردي دائري مغلف بفيلم ، محفور عليه &quot;R 40&quot; على جانب واحد وسهل على الجانب الآخر.</p><p dir="RTL" style="text-align:right">قرص وردي دائري مغلف بفيلم ، محفور عليه&quot;R 20&quot; على جانب واحد وسهل على الجانب الآخر.</p><p dir="RTL" style="text-align:right">قرص وردي دائري مغلف بفيلم ، محفور عليه&quot;R 10&quot; على جانب واحد وسهل على الجانب الآخر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المصنعة وصاحبة حقوق التسويق </strong></p><p dir="RTL">الشركة العمانية لمستحضرات الصيدلة ش.م.م</p><p>&nbsp;صلالة، سلطنة عمان</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم تحديث هذه النشرة آخر مرة في أكتوبر 2018

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zyrosa 10mg film coated tablets
 Zyrosa 20mg film coated tablets
 Zyrosa 40mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10 mg: Each tablet contains 10 mg rosuvastatin (as rosuvastatin calcium).
20 mg: Each tablet contains 20 mg rosuvastatin (as rosuvastatin calcium
40 mg: Each tablet contains 40 mg rosuvastatin (as rosuvastatin calcium)

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet (Tablet).
10mg: Pink, round shaped, film coated tablets debossed with “R10” on one side and plain on other side.
20mg: Pink, round shaped, film coated tablets debossed with “R20” on one side and plain on other side.
40mg: Pink, round shaped, film coated tablets debossed with “R40” on one side and plain on other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Adults, adolescents and children aged 6 years or older with primary hypercholesterolaemia (type IIa including heterozygous familial hypercholesterolaemia) or mixed dyslipidaemia (type IIb) as an adjunct to diet when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate.</p><p style="text-align:justify">Adults, adolescents and children aged 6 years or older with homozygous familial hypercholesterolaemia as an adjunct to diet and other lipid lowering treatments (e.g. LDL apheresis) or if such treatments are not appropriate.</p><p style="text-align:justify">Prevention of Cardiovascular Events</p><p style="text-align:justify">Prevention of major cardiovascular events in patients who are estimated to have a high risk for a first cardiovascular event (see Section 5.1), as an adjunct to correction of other risk factors.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify">Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment. The dose should be individualized according to the goal of therapy and patient response, using current consensus guidelines.</p><p style="text-align:justify">Zyrosa may be given at any time of day, with or without food.</p><p style="text-align:justify"><strong>Treatment of hypercholesterolaemia</strong></p><p style="text-align:justify">The recommended start dose is 5 or 10 mg orally once daily in both statin na&iuml;ve or patients switched from another HMG CoA reductase inhibitor. The choice of start dose should take into account the individual patient&#39;s cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below). A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see Section 5.1). In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see Section 4.8), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow-up will be performed (see Section 4.4). Specialist supervision is recommended when the 40 mg dose is initiated.</p><p style="text-align:justify"><strong>Prevention of cardiovascular events</strong></p><p style="text-align:justify">In the cardiovascular events risk reduction study, the dose used was 20 mg daily (see Section 5.1).</p><p style="text-align:justify"><strong>Paediatric population</strong></p><p style="text-align:justify">Paediatric use should only be carried out by specialists.</p><p style="text-align:justify"><u>Children and adolescents 6 to 17 years of age (Tanner Stage &lt;II-V)</u> <u>Heterozygous familial hypercholesterolaemia</u></p><p style="text-align:justify">In children and adolescents with heterozygous familial hypercholesterolaemia the usual start dose is 5 mg daily.</p><p style="text-align:justify">&bull;&nbsp;&nbsp; In children 6 to 9 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-10 mg orally once daily. Safety and efficacy of doses greater than 10 mg have not been studied in this population.</p><p style="text-align:justify">&bull;&nbsp;&nbsp;&nbsp; In children 10 to 17 years of age with heterozygous familial hypercholesterolaemia, the usual dose range is 5-20 mg orally once daily. Safety and efficacy of doses greater than 20 mg have not been studied in this population.</p><p style="text-align:justify">Titration should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see Section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p style="text-align:justify"><u>Homozygous familial hypercholesterolaemia</u></p><p style="text-align:justify">In children 6 to 17 years of age with homozygous familial hypercholesterolaemia, the recommended maximum dose is 20 mg once daily.</p><p style="text-align:justify">A starting dose of 5 to 10 mg once daily depending on age, weight and prior statin use is advised. Titration to the maximum dose of 20 mg once daily should be conducted according to the individual response and tolerability in paediatric patients, as recommended by the paediatric treatment recommendations (see section 4.4). Children and adolescents should be placed on standard cholesterol-lowering diet before rosuvastatin treatment initiation; this diet should be continued during rosuvastatin treatment.</p><p style="text-align:justify">There is limited experience with doses other than 20 mg in this population. The 40 mg tablet is not suitable for use in paediatric patients.</p><p style="text-align:justify"><u>Children younger than 6 years</u></p><p style="text-align:justify">The safety and efficacy of use in children younger than 6 years has not been studied. Therefore, Zyrosa is not recommended for use in children younger than 6 years.</p><p style="text-align:justify"><strong>Use in the elderly</strong></p><p style="text-align:justify">A start dose of 5 mg is recommended in patients &gt;70 years (see Section 4.4). No other dose adjustment is necessary in relation to age.</p><p style="text-align:justify"><strong>Dosage in patients with renal insufficiency</strong></p><p style="text-align:justify">No dose adjustment is necessary in patients with mild to moderate renal impairment. The recommended start dose is 5 mg in patients with moderate renal impairment (creatinine clearance of &lt;60 ml/min). The 40 mg dose is contraindicated in patients with moderate renal impairment. The use of Zyrosa in patients with severe renal impairment is contraindicated for all doses (see Section 4.3 and Section 5.2).</p><p style="text-align:justify"><strong>Dosage in patients with hepatic impairment</strong></p><p style="text-align:justify">There was no increase in systemic exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, increased systemic exposure has been observed in subjects with Child-Pugh scores of 8 and 9 (see Section 5.2). In these patients an assessment of renal function should be considered (see Section 4.4). There is no experience in subjects with Child-Pugh scores above 9. Zyrosa is contraindicated in patients with active liver disease (see Section 4.3).</p><p style="text-align:justify"><strong>Race</strong></p><p style="text-align:justify">Increased systemic exposure has been seen in Asian subjects (see Section 4.3, Section 4.4 and Section 5.2). The recommended start dose is 5 mg for patients of Asian ancestry. The 40 mg dose is contraindicated in these patients.</p><p style="text-align:justify"><strong>Genetic polymorphisms</strong></p><p style="text-align:justify">Specific types of genetic polymorphisms are known that can lead to increased rosuvastatin exposure (see Section 5.2). For patients who are known to have such specific types of polymorphisms, a lower daily dose of Zyrosa is recommended.</p><p style="text-align:justify"><strong>Dosage in patients with pre-disposing factors to myopathy</strong></p><p style="text-align:justify">The recommended start dose is 5 mg in patients with predisposing factors to myopathy (see Section 4.4).</p><p style="text-align:justify">The 40 mg dose is contraindicated in some of these patients (see Section 4.3).</p><p style="text-align:justify"><strong>Concomitant therapy</strong></p><p style="text-align:justify">Rosuvastatin is a substrate of various transporter proteins (e.g. OATP1B1 and BCRP). The risk of myopathy (including rhabdomyolysis) is increased when Zyrosa is administered concomitantly with certain medicinal products that may increase the plasma concentration of rosuvastatin due to interactions with these transporter proteins (e.g. ciclosporin and certain protease inhibitors including combinations of ritonavir with atazanavir, lopinavir, and/or tipranavir; see Sections 4.4 and 4.5). Whenever possible, alternative medications should be considered, and, if necessary, consider temporarily discontinuing Zyrosa therapy. In situations where co-administration of these medicinal products with Zyrosa is unavoidable, the benefit and the risk of concurrent treatment and Zyrosa dosing adjustments should be carefully considered (see Section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zyrosa is contraindicated:
-	in patients with hypersensitivity to rosuvastatin or to any of the excipients.
-	in patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal (ULN).
-	in patients with severe renal impairment (creatinine clearance <30 ml/min).
-	in patients with myopathy.
-	in patients receiving concomitant ciclosporin.
-	during pregnancy and lactation and in women of childbearing potential not using appropriate contraceptive measures.
 
The	40	mg	dose	is	contraindicated	in	patients	with	pre-disposing	factors	for myopathy/rhabdomyolysis. Such factors include:
−	moderate renal impairment (creatinine clearance < 60 ml/min)
−	hypothyroidism
−	personal or family history of hereditary muscular disorders
−	previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate
−	alcohol abuse
−	situations where an increase in plasma levels may occur
−	Asian patients
−	concomitant use of fibrates. (see Sections 4.4, 4.5 and 5.2)

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Renal Effects</u></p><p style="text-align:justify">Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with higher doses of Zyrosa, in particular 40 mg, where it was transient or intermittent in most cases. Proteinuria has not been shown to be predictive of acute or progressive renal disease (see Section 4.8). The reporting rate for serious renal events in post- marketing use is higher at the 40 mg dose. An assessment of renal function should be considered during routine follow-up of patients treated with a dose of 40 mg.</p><p style="text-align:justify"><u>Skeletal Muscle Effects</u></p><p style="text-align:justify">Effects on skeletal muscle e.g. myalgia, myopathy and, rarely, rhabdomyolysis have been reported in Zyrosa-treated patients with all doses and in particular with doses &gt; 20 mg. Very rare cases of rhabdomyolysis have been reported with the use of ezetimibe in combination with HMG-CoA reductase inhibitors. A pharmacodynamic interaction cannot be excluded (see Section 4.5) and caution should be exercised with their combined use.</p><p style="text-align:justify">As with other HMG-CoA reductase inhibitors, the reporting rate for rhabdomyolysis associated with Zyrosa in post-marketing use is higher at the 40 mg dose.</p><p style="text-align:justify"><em>Creatine Kinase Measurement</em></p><p style="text-align:justify">Creatine Kinase (CK) should not be measured following strenuous exercise or in the presence of a plausible alternative cause of CK increase which may confound interpretation of the result. If CK levels are significantly elevated at baseline (&gt;5xULN) a confirmatory test should be carried out within 5 &ndash; 7 days. If the repeat test confirms a baseline CK &gt;5xULN, treatment should not be started.</p><p style="text-align:justify"><em>Before Treatment</em></p><p style="text-align:justify">Zyrosa, as with other HMG-CoA reductase inhibitors, should be prescribed with caution in patients with pre-disposing factors for myopathy/rhabdomyolysis. Such factors include:</p><p style="text-align:justify">&bull;&nbsp; renal impairment</p><p style="text-align:justify">&bull;&nbsp; hypothyroidism</p><p style="text-align:justify">&bull;&nbsp; personal or family history of hereditary muscular disorders</p><p style="text-align:justify">&bull;&nbsp; previous history of muscular toxicity with another HMG-CoA reductase inhibitor or fibrate</p><p style="text-align:justify">&bull;&nbsp; alcohol abuse</p><p style="text-align:justify">&bull;&nbsp; age &gt;70 years</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">&bull;&nbsp; situations where an increase in plasma levels may occur (see Sections 4.2, 4.5 and 5.2)</p><p style="text-align:justify">&bull;&nbsp; concomitant use of fibrates.</p><p style="text-align:justify">In such patients the risk of treatment should be considered in relation to possible benefit and clinical monitoring is recommended. If CK levels are significantly elevated at baseline (&gt;5xULN) treatment should not be started.</p><p style="text-align:justify"><em>Whilst on Treatment</em></p><p style="text-align:justify">Patients should be asked to report inexplicable muscle pain, weakness or cramps immediately, particularly if associated with malaise or fever. CK levels should be measured in these patients. Therapy should be discontinued if CK levels are markedly elevated (&gt;5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are &le; 5x ULN). If symptoms resolve and CK levels return to normal, then consideration should be given to re- introducing Zyrosa or an alternative HMG-CoA reductase inhibitor at the lowest dose with close monitoring. Routine monitoring of CK levels in asymptomatic patients is not warranted. There have been very rare reports of an immune-mediated necrotising myopathy (IMNM) during or after treatment with statins, including rosuvastatin. IMNM is clinically characterised by proximal muscle weakness and elevated serum creatine kinase, which persist despite discontinuation of statin treatment.</p><p style="text-align:justify">In clinical trials there was no evidence of increased skeletal muscle effects in the small number of patients dosed with Zyrosa and concomitant therapy. However, an increase in the incidence of myositis and myopathy has been seen in patients receiving other HMG-CoA reductase inhibitors together with fibric acid derivatives including gemfibrozil, ciclosporin, nicotinic acid, azole antifungals, protease inhibitors and macrolide antibiotics. Gemfibrozil increases the risk of myopathy when given concomitantly with some HMG-CoA reductase inhibitors. Therefore, the combination of Zyrosa and gemfibrozil is not recommended. The benefit of further alterations in lipid levels by the combined use of Zyrosa with fibrates or niacin should be carefully weighed against the potential risks of such combinations. The 40 mg dose is contraindicated with concomitant use of a fibrate (see Section 4.5 and Section 4.8).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">Crestor must not be co-administered with systemic formulations of fusidic acid or within 7 days of stopping fusidic acid treatment. In patients where the use of systemic fusidic acid is considered essential, statin treatment should be discontinued throughout the duration of fusidic acid treatment. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving fusidic acid and statins in combination (see section 4.5). Patients should be advised to seek medical advice immediately if they experience any symptoms of muscle weakness, pain or tenderness. Statin therapy may be re-introduced seven days after the last dose of fusidic acid. In exceptional circumstances, where prolonged systemic fusidic acid is needed, e.g. for the treatment of severe infections, the need for co-administration of Crestor and fusidic acid should only be considered on a case by case basis and under close medical supervision.</p><p style="text-align:justify">Zyrosa should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><u>Liver Effects</u></p><p style="text-align:justify">As with other HMG-CoA reductase inhibitors, Zyrosa should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.</p><p style="text-align:justify">It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment. Zyrosa should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal. The reporting rate for serious hepatic events (consisting mainly of increased hepatic transaminases) in post- marketing use is higher at the 40 mg dose.</p><p style="text-align:justify">In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Zyrosa.</p><p style="text-align:justify"><u>Race</u></p><p style="text-align:justify">Pharmacokinetic studies show an increase in exposure in Asian subjects compared with Caucasians (see Section 4.2, Section 4.3 and Section 5.2).</p><p style="text-align:justify"><u>Protease inhibitors</u></p><p style="text-align:justify">Increased systemic exposure to rosuvastatin has been observed in subjects receiving rosuvastatin concomitantly with various protease inhibitors in combination with ritonavir. Consideration should be given both to the benefit of lipid lowering by use of Zyrosa in HIV patients receiving protease inhibitors and the potential for increased rosuvastatin plasma concentrations when initiating and up titrating Zyrosa doses in patients treated with protease inhibitors. The concomitant use with certain protease inhibitors is not recommended unless the dose of Zyrosa is adjusted (see Sections 4.2 and 4.5).</p><p style="text-align:justify"><u>Lactose intolerance</u></p><p style="text-align:justify">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p style="text-align:justify"><u>Interstitial lung disease</u></p><p style="text-align:justify">Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see Section 4.8). Presenting features can include dyspnoea, non- productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.</p><p style="text-align:justify"><u>Diabetes Mellitus</u></p><p style="text-align:justify">Some evidence suggests that statins as a class raise blood glucose and in some patients, at high risk of future diabetes, may produce a level of hyperglycaemia where formal diabetes care is appropriate. This risk, however, is outweighed by the reduction in vascular risk with statins and therefore should not be a reason for stopping statin treatment. Patients at risk (fasting glucose 5.6 to 6.9 mmol/l, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, hypertension) should be monitored both clinically and biochemically according to national guidelines.</p><p style="text-align:justify">In the JUPITER study, the reported overall frequency of diabetes mellitus was 2.8% in rosuvastatin and 2.3% in placebo, mostly in patients with fasting glucose 5.6 to 6.9 mmol/l.</p><p style="text-align:justify"><u>Paediatric population</u></p><p style="text-align:justify">The evaluation of linear growth (height), weight, BMI (body mass index), and secondary characteristics of sexual maturation by Tanner staging in paediatric patients 6 to 17 years of age taking rosuvastatin is limited to a two-year period. After two years of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see Section 5.1).</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">In a clinical trial of children and adolescents receiving rosuvastatin for 52 weeks, CK elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently compared to observations in clinical trials in adults (see Section 4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><u>Effect of co-administered medicinal products on rosuvastatin</u></p><p style="text-align:justify"><strong>Transporter protein inhibitors: </strong>Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter OATP1B1 and efflux transporter BCRP. Concomitant administration of Zyrosa with medicinal products that are inhibitors of these transporter proteins may result in increased rosuvastatin plasma concentrations and an increased risk of myopathy (see Sections 4.2, 4.4 and 4.5 Table 1).</p><p style="text-align:justify"><strong>Ciclosporin: </strong>During concomitant treatment with Zyrosa and ciclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Table 1). Zyrosa is contraindicated in patients receiving concomitant ciclosporin (see Section 4.3). Concomitant administration did not affect plasma concentrations of ciclosporin.</p><p style="text-align:justify"><strong>Protease inhibitors: </strong>Although the exact mechanism of interaction is unknown, concomitant protease inhibitor use may strongly increase rosuvastatin exposure (see Table 1). For instance, in a pharmacokinetic study, co-administration of 10 mg rosuvastatin and a combination product of two protease inhibitors (300 mg atazanavir / 100 mg ritonavir) in healthy volunteers was associated with an approximately three-fold and seven-fold increase in rosuvastatin AUC and C<sub>max</sub>respectively. The concomitant use of Zyrosa and some protease inhibitor combinations may be considered after careful consideration of Zyrosa dose adjustments based on the expected increase in rosuvastatin exposure (see Sections 4.2, 4.4 and</p><p style="text-align:justify">4.5&nbsp; Table 1).</p><p style="text-align:justify"><strong>Gemfibrozil and other lipid-lowering products</strong>: Concomitant&nbsp; use&nbsp; of&nbsp; Zyrosa&nbsp; and gemfibrozil resulted in a 2-fold increase in rosuvastatin C <sub>max</sub> and AUC (see Section 4.4).</p><p style="text-align:justify">Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur. Gemfibrozil, fenofibrate, other fibrates and lipid lowering doses (&gt; or equal to 1g/day) of niacin (nicotinic acid) increase the risk of myopathy when given concomitantly with HMG-CoA reductase inhibitors, probably because they can produce myopathy when given alone. The 40 mg dose is contraindicated with concomitant use of a fibrate (see Sections 4.3 and 4.4). These patients should also start with the 5 mg dose.</p><p style="text-align:justify"><strong>Ezetimibe: </strong>Concomitant use of 10 mg Zyrosa and 10 mg ezetimibe resulted in a 1.2 fold increase in AUC of rosuvastatin in hypercholesterolaemic subjects (Table 1). A pharmacodynamic interaction, in terms of adverse effects, between Zyrosa and ezetimibe cannot be ruled out (see Section 4.4).</p><p style="text-align:justify"><strong>Antacid</strong>: The simultaneous dosing of Zyrosa with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%. This effect was mitigated when the antacid was dosed 2 hours after Zyrosa. The clinical relevance of this interaction has not been studied.</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify"><strong>Erythromycin: </strong>Concomitant use of Zyrosa and erythromycin resulted in a 20% decrease in AUC and a 30% decrease in C<sub>max</sub> of rosuvastatin. This interaction may be caused by&nbsp; the increase in gut motility caused by erythromycin.</p><p style="text-align:justify"><strong>Cytochrome P450 enzymes: </strong>Results from <em>in vitro </em>and <em>in vivo </em>studies show that rosuvastatin is neither an inhibitor nor an inducer of cytochrome P450 isoenzymes. In addition, rosuvastatin is a poor substrate for these isoenzymes. Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected. No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and CYP3A4).</p><p style="text-align:justify"><strong>Interactions requiring rosuvastatin dose adjustments (see also Table 1): </strong>When it is necessary to co-administer Zyrosa with other medicinal products known to increase exposure to rosuvastatin, doses of Zyrosa should be adjusted. Start with a 5 mg once daily dose of Zyrosa if the expected increase in exposure (AUC) is approximately 2-fold or higher. The maximum daily dose of Zyrosa should be adjusted so that the expected rosuvastatin exposure would not likely exceed that of a 40 mg daily dose of Zyrosa taken without interacting medicinal products, for example a 20 mg dose of Zyrosa with gemfibrozil (1.9-fold increase), and a 10 mg dose of Zyrosa with combination ritonavir/atazanavir (3.1-fold increase).</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td colspan="3" style="vertical-align:top"><p><strong>Table 1 Effect of co-administered medicinal products on rosuvastatin exposure (AUC; in order of decreasing magnitude) from published clinical trials</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Interacting drug dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Rosuvastatin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dose regimen</strong></p></td><td style="vertical-align:top"><p><strong>Change&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in</strong></p><p><strong>rosuvastatin AUC<sup>*</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ciclosporin 75 mg BID to 200 mg BID, 6 months</p></td><td style="vertical-align:top"><p>10 mg OD, 10 days</p></td><td style="vertical-align:top"><p>7.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 300 mg/ritonavir 100 mg OD,</p><p>8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>3.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Simeprevir 150 mg OD, 7 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>2.8-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir 400 mg/ritonavir 100 mg BID,</p><p>17 days</p></td><td style="vertical-align:top"><p>20 mg OD, 7 days</p></td><td style="vertical-align:top"><p>2.1-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Clopidogrel 300 mg loading, followed by 75 mg at 24 hours</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Gemfibrozil 600 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>1.9-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Eltrombopag 75 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.6-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir 600 mg/ritonavir 100 mg BID,</p><p>7 days</p></td><td style="vertical-align:top"><p>10 mg OD, 7 days</p></td><td style="vertical-align:top"><p>1.5-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir 500 mg/ritonavir 200 mg BID,</p><p>11 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Dronedarone 400 mg BID</p></td><td style="vertical-align:top"><p>Not available</p></td><td style="vertical-align:top"><p>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole 200 mg OD, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p><sup>**</sup>1.4-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Ezetimibe 10 mg OD, 14 days</p></td><td style="vertical-align:top"><p>10 mg, OD, 14 days</p></td><td style="vertical-align:top"><p><sup>**</sup>1.2-fold &uarr;</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir 700 mg/ritonavir 100 mg</p><p>BID, 8 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Aleglitazar 0.3 mg, 7 days</p></td><td style="vertical-align:top"><p>40 mg, 7 days</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Silymarin 140 mg TID, 5 days</p></td><td style="vertical-align:top"><p>10 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Fenofibrate 67 mg TID, 7 days</p></td><td style="vertical-align:top"><p>10 mg, 7 days</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Rifampin 450 mg OD, 7 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole 200 mg BID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole 200 mg OD, 11 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>&harr;</p></td></tr><tr><td style="vertical-align:top"><p>Erythromycin 500 mg QID, 7 days</p></td><td style="vertical-align:top"><p>80 mg, single dose</p></td><td style="vertical-align:top"><p>20% &darr;</p></td></tr><tr><td style="vertical-align:top"><p>Baicalin 50 mg TID, 14 days</p></td><td style="vertical-align:top"><p>20 mg, single dose</p></td><td style="vertical-align:top"><p>47% &darr;</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><sup>*</sup>Data given as x-fold change represent a simple ratio between co-administration and rosuvastatin</p><p>alone. Data given as % change represent % difference relative to rosuvastatin alone. Increase is indicated as &ldquo;&uarr;&ldquo;, no change as <strong>&ldquo;</strong>&harr;&rdquo;, decrease as &ldquo;&darr;&rdquo;.</p><p><sup>**</sup>Several interaction studies have been performed at different Zyrosa&nbsp; dosages, the table&nbsp; shows&nbsp;&nbsp; the most significant ratio</p><p>OD = once daily; BID = twice daily; TID = three times daily; QID = four times daily</p></td></tr></tbody></table><p style="text-align:justify"><u>Effect of rosuvastatin on co-administered medicinal products</u></p><p style="text-align:justify"><strong>Vitamin K antagonists: </strong>As with other HMG-CoA reductase inhibitors, the initiation of treatment or dosage up-titration of Zyrosa in patients treated concomitantly with vitamin K antagonists (e.g. warfarin or another coumarin anticoagulant) may result in an increase in International Normalised Ratio (INR). Discontinuation or down-titration of Zyrosa may result in a decrease in INR. In such situations, appropriate monitoring of INR is desirable.</p><p style="text-align:justify"><strong>Oral contraceptive/hormone replacement therapy (HRT): </strong>Concomitant use of Zyrosa and an oral contraceptive resulted in an increase in ethinyl estradiol and norgestrel AUC of 26% and 34%, respectively. These increased plasma levels should be considered when selecting oral contraceptive doses. There are no pharmacokinetic data available in subjects taking concomitant Zyrosa and HRT and therefore a similar effect cannot be excluded. However, the combination has been extensively used in women in clinical trials and was well tolerated.</p><p style="text-align:justify">Other medicinal products:</p><p style="text-align:justify"><strong>Digoxin: </strong>Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.</p><p style="text-align:justify"><u>Fusidic Acid:</u> Interaction studies with rosuvastatin and fusidic acid have not been conducted. The risk of myopathy, including rhabdomyolysis may be increased by the concomitant administration of systemic fusidic acid with statins. The mechanism of this interaction (whether it is pharmacodynamic or pharmacokinetic, or both) is yet unknown. There have been reports of rhabdomyolysis (including some fatalities) in patients receiving this combination.</p><p style="text-align:justify">If treatment with systemic fusidic acid is necessary, Crestor treatment should be discontinued throughout the duration of the fusidic acid treatment. <strong>Also see section 4.4.</strong></p><p style="text-align:justify"><strong>Paediatric population: </strong>Interaction studies have only been performed in adults. The extent of interactions in the paediatric population is not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zyrosa is contraindicated in pregnancy and lactation.</p><p>Women of child bearing potential should use appropriate contraceptive measures.</p><p>Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy. Animal studies provide limited evidence of reproductive toxicity (see Section 5.3). If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.</p><p>Rosuvastatin is excreted in the milk of rats. There are no data with respect to excretion in milk in humans (see Section 4.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies to determine the effect of Zyrosa on the ability to drive and use machines have not been conducted. However, based on its pharmacodynamic properties, Zyrosa is unlikely to affect this ability. When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The adverse reactions seen with Zyrosa are generally mild and transient. In controlled clinical trials, less than 4% of Zyrosa-treated patients were withdrawn due to adverse reactions.</p><p><u>Tabulated list of adverse reactions</u></p><p>Based on data from clinical studies and extensive post-marketing experience, the following table presents the adverse reaction profile for rosuvastatin. Adverse reactions listed below are classified according to frequency and system organ class (SOC).</p><p>The frequencies of adverse reactions are ranked according to the following convention: Common (&ge;1/100 to &lt;1/10); Uncommon (&ge;1/1,000 to &lt;1/100); Rare (&ge;1/10,000 to &lt;1/1000); Very rare (&lt;1/10,000); Not known (cannot be estimated from the available data).</p><p><strong>Table 2. Adverse reactions based on data from clinical studies and post-marketing experience</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Very rare</strong></p></td><td style="vertical-align:top"><p><strong>Not known</strong></p></td></tr><tr><td style="vertical-align:top"><p><em>Blood&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</em></p><p><em>lymphatic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytope nia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Immune&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions including angioedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Endocrine disorders</em></p></td><td style="vertical-align:top"><p>Diabetes mellitus<sup>1</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Psychiatric</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Depression</p></td></tr><tr><td style="vertical-align:top"><p><em>disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Nervous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; system disorders</em></p></td><td style="vertical-align:top"><p>Headache Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Polyneuropat hy</p><p>Memory loss</p></td><td style="vertical-align:top"><p>Peripheral neuropathy Sleep disturbances (including insomnia and nightmares)</p></td></tr><tr><td style="vertical-align:top"><p><em>Respiratory, thoracic&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and mediastinal disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough Dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Gastro-intestinal disorders</em></p></td><td style="vertical-align:top"><p>Constipation Nausea Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p><em>Hepatobiliary disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Increased hepatic transaminases</p></td><td style="vertical-align:top"><p>Jaundice Hepatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Skin&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and</em></p><p><em>subcutaneous tissue disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pruritis Rash Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Stevens- Johnson syndrome</p></td></tr><tr><td style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Myopathy (including myositis) Rhabdomyolysis</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Tendon disorders, sometimes complicated by rupture Immune- mediated necrotising myopathy</p></td></tr><tr><td style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomas tia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><em>General&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; disorders and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; administration</em></p><p><em>site conditions</em></p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema</p></td></tr><tr><td colspan="6" style="vertical-align:top"><p><sup>1</sup> Frequency will depend on the presence or absence of risk factors (fasting blood glucose &ge; 5.6 mmol/L, BMI &gt;30 kg/m<sup>2</sup>, raised triglycerides, history of hypertension).</p></td></tr></tbody></table><p>As with other HMG-CoA reductase inhibitors, the incidence of adverse drug reactions tends to be dose dependent.</p><p><strong>Renal effects: </strong>Proteinuria, detected by dipstick testing and mostly tubular in origin, has been observed in patients treated with Zyrosa. Shifts in urine protein from none or trace to ++ or more were seen in &lt;1% of patients at some time during treatment with 10 and 20 mg, and in approximately 3% of patients treated with 40 mg. A minor increase in shift from none or trace to + was observed with the 20 mg dose. In most cases, proteinuria decreases or disappears spontaneously on continued therapy. Review of data from clinical trials and post-marketing experience to date has not identified a causal association between proteinuria and acute or progressive renal disease.</p><p>Haematuria has been observed in patients treated with Zyrosa and clinical trial data show that the occurrence is low.</p><p><strong>Skeletal muscle effects: </strong>Effects on skeletal muscle e.g. myalgia, myopathy (including myositis) and, rarely, rhabdomyolysis with and without acute renal failure have been reported in Zyrosa-treated patients with all doses and in particular with doses &gt; 20 mg.</p><p>A dose-related increase in CK levels has been observed in patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient. If CK levels are elevated (&gt;5xULN), treatment should be discontinued (see Section 4.4).</p><p><strong>Liver effects: </strong>As with other HMG-CoA reductase inhibitors, a dose-related increase in transaminases has been observed in a small number of patients taking rosuvastatin; the majority of cases were mild, asymptomatic and transient.</p><p>The following adverse events have been reported with some statins: Sexual dysfunction.</p><p>Exceptional cases of interstitial lung disease, especially with long term therapy (see Section 4.4).</p><p>The reporting rates for rhabdomyolysis, serious renal events and serious hepatic events (consisting mainly of increased hepatic transaminases) is higher at the 40 mg dose.</p><p><strong>Paediatric population: </strong>Creatine kinase elevations &gt;10xULN and muscle symptoms following exercise or increased physical activity were observed more frequently in a 52-week clinical trial of children and adolescents compared to adults (see Section 4.4). In other respects, the safety profile of rosuvastatin was similar in children and adolescents compared to adults.</p><p><strong>To report any side effect(s):</strong></p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>National Pharmacovigilance &amp; Drug Safety Centre (NPC)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Fax: +966-11-205-7662</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Toll free phone: 8002490000</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>E-mail: &nbsp;</strong><strong><u>npc.drug@sfda.gov.sa</u></strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Website: &nbsp;</strong><strong>www.sfda.gov.sa/npc</strong></p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p><strong>&nbsp;&nbsp;</strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC states:&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Please contact the relevant competent authority</strong></p><p><strong>&nbsp;</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of overdose. In the event of overdose, the patient should be treated symptomatically and supportive measures instituted as required. Liver function and CK levels should be monitored. Haemodialysis is unlikely to be of benefit.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Pharmacotherapeutic group: </strong>HMG-CoA reductase inhibitors</p><p><strong>ATC code: </strong>C10A A07</p><p>Mechanism of action</p><p>Rosuvastatin is a selective and competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor for cholesterol. The primary site of action of rosuvastatin is the liver, the target organ for cholesterol lowering.</p><p>Rosuvastatin increases the number of hepatic LDL receptors on the cell-surface, enhancing uptake and catabolism of LDL and it inhibits the hepatic synthesis of VLDL, thereby reducing the total number of VLDL and LDL particles.</p><p>Pharmacodynamic effects</p><p>Zyrosa reduces elevated LDL-cholesterol, total cholesterol and triglycerides and increases HDL-cholesterol. It also lowers ApoB, nonHDL-C, VLDL-C, VLDL-TG and increases ApoA-I (see Table 3). Zyrosa also lowers the LDL-C/HDL-C, total C/HDL-C and nonHDL- C/HDL-C and the ApoB/ApoA-I ratios.</p><p>Table 3 Dose response in patients with primary hypercholesterolaemia (type IIa and IIb) (adjusted mean percent change from baseline)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>N</strong></p></td><td style="vertical-align:top"><p><strong>LDL-C</strong></p></td><td style="vertical-align:top"><p><strong>Total-C</strong></p></td><td style="vertical-align:top"><p><strong>HDL-C</strong></p></td><td style="vertical-align:top"><p><strong>TG</strong></p></td><td style="vertical-align:top"><p><strong>nonHDL- C</strong></p></td><td style="vertical-align:top"><p><strong>ApoB</strong></p></td><td style="vertical-align:top"><p><strong>ApoA-I</strong></p></td></tr><tr><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-5</p></td><td style="vertical-align:top"><p>3</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>-7</p></td><td style="vertical-align:top"><p>-3</p></td><td style="vertical-align:top"><p>0</p></td></tr><tr><td style="vertical-align:top"><p>5</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-45</p></td><td style="vertical-align:top"><p>-33</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>-35</p></td><td style="vertical-align:top"><p>-44</p></td><td style="vertical-align:top"><p>-38</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-52</p></td><td style="vertical-align:top"><p>-36</p></td><td style="vertical-align:top"><p>14</p></td><td style="vertical-align:top"><p>-10</p></td><td style="vertical-align:top"><p>-48</p></td><td style="vertical-align:top"><p>-42</p></td><td style="vertical-align:top"><p>4</p></td></tr><tr><td style="vertical-align:top"><p>20</p></td><td style="vertical-align:top"><p>17</p></td><td style="vertical-align:top"><p>-55</p></td><td style="vertical-align:top"><p>-40</p></td><td style="vertical-align:top"><p>8</p></td><td style="vertical-align:top"><p>-23</p></td><td style="vertical-align:top"><p>-51</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>5</p></td></tr><tr><td style="vertical-align:top"><p>40</p></td><td style="vertical-align:top"><p>18</p></td><td style="vertical-align:top"><p>-63</p></td><td style="vertical-align:top"><p>-46</p></td><td style="vertical-align:top"><p>10</p></td><td style="vertical-align:top"><p>-28</p></td><td style="vertical-align:top"><p>-60</p></td><td style="vertical-align:top"><p>-54</p></td><td style="vertical-align:top"><p>0</p></td></tr></tbody></table><p>A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks. The maximum response is usually achieved by 4 weeks and is maintained after that.</p><p><strong>Clinical efficacy and safety</strong></p><p>Zyrosa is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia, regardless of race, sex, or age and in special populations such as diabetics, or patients with familial hypercholesterolaemia.</p><p>From pooled phase III data, Zyrosa has been shown to be effective at treating the majority of patients with type IIa and IIb hypercholesterolaemia (mean baseline LDL-C about 4.8 mmol/l) to recognised European Atherosclerosis Society (EAS; 1998) guideline targets; about 80% of patients treated with 10 mg reached the EAS targets for LDL-C levels (&lt;3 mmol/l).</p><p>In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given Zyrosa from 20 mg to 80 mg in a force-titration design. All doses showed a beneficial effect on lipid parameters and treatment to target goals. Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C was reduced by 53%. 33% of patients reached EAS guidelines for LDL-C levels (&lt;3 mmol/l).</p><p>In a force-titration, open label trial, 42 patients with homozygous familial hypercholesterolaemia were evaluated for their response to Zyrosa 20 - 40 mg. In the overall population, the mean LDL-C reduction was 22%.</p><p>In clinical studies with a limited number of patients, Zyrosa has been shown to have additive efficacy in lowering triglycerides when used in combination with fenofibrate and in increasing HDL-C levels when used in combination with niacin (see Section 4.4).</p><p>In a multi-centre, double-blind, placebo-controlled clinical study (METEOR), 984 patients between 45 and 70 years of age and at low risk for coronary heart disease (defined as Framingham risk &lt;10% over 10 years), with a mean LDL-C of 4.0 mmol/l (154.5 mg/dL), but with subclinical atherosclerosis (detected by Carotid Intima Media Thickness) were randomised to 40 mg rosuvastatin once daily or placebo for 2 years. Rosuvastatin significantly slowed the rate of progression of the maximum CIMT for the 12 carotid artery sites compared to placebo by -0.0145 mm/year [95% confidence interval -0.0196, -0.0093; p&lt;0.0001]. The change from baseline was -0.0014 mm/year (-0.12%/year (non-significant)) for rosuvastatin compared to a progression of +0.0131 mm/year (1.12%/year (p&lt;0.0001)) for placebo. No direct correlation between CIMT decrease and reduction of the risk of cardiovascular events has yet been demonstrated. The population studied in METEOR is low risk for coronary heart disease and does not represent the target population of Zyrosa 40mg. The 40mg dose should only be prescribed in patients with severe hypercholesterolaemia at high cardiovascular risk (see Section 4.2).</p><p>In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin on the occurrence of major atherosclerotic cardiovascular disease events was assessed in 17,802 men (&ge;50 years) and women (&ge;60 years).</p><p>Study participants were randomly assigned to placebo (n=8901) or rosuvastatin 20 mg once daily (n=8901) and were followed for a mean duration of 2 years.</p><p>LDL-cholesterol concentration was reduced by 45% (p&lt;0.001) in the rosuvastatin group compared to the placebo group.</p><p>In a post-hoc analysis of a high-risk subgroup of subjects with a baseline Framingham risk score &gt;20% (1558 subjects) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.028) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate per 1000 patient-years was 8.8. Total mortality was unchanged in this high risk group (p=0.193). In a post-hoc analysis of a high-risk subgroup of subjects (9302 subjects total) with a baseline SCORE risk &ge;5% (extrapolated to include subjects above 65 yrs) there was a significant reduction in the combined end-point of cardiovascular death, stroke and myocardial infarction (p=0.0003) on rosuvastatin treatment versus placebo. The absolute risk reduction in the event rate was 5.1 per 1000 patient-years. Total mortality was unchanged in this high risk group (p=0.076).</p><p>In the JUPITER trial there were 6.6% of rosuvastatin and 6.2% of placebo subjects who discontinued use of study medication due to an adverse event. The most common adverse events that led to treatment discontinuation were: myalgia (0.3% rosuvastatin, 0.2% placebo), abdominal pain (0.03% rosuvastatin, 0.02% placebo) and rash (0.02% rosuvastatin, 0.03% placebo). The most common adverse events at a rate greater than or equal to placebo were urinary tract infection (8.7% rosuvastatin, 8.6% placebo), nasopharyngitis (7.6% rosuvastatin, 7.2% placebo), back pain (7.6% rosuvastatin, 6.9% placebo) and myalgia (7.6% rosuvastatin,6.6% placebo).</p><p><strong>Paediatric population</strong></p><p>In a double-blind, randomized, multi-centre, placebo-controlled, 12-week study (n=176, 97 male and 79 female) followed by a 40-week (n=173, 96 male and 77 female), open-label, rosuvastatin dose-titration phase, patients 10-17 years of age (Tanner stage II-V, females at least 1 year post-menarche) with heterozygous familial hypercholesterolaemia received rosuvastatin 5, 10 or 20 mg or placebo daily for 12 weeks and then all received rosuvastatin daily for 40 weeks. At study entry, approximately 30% of the patients were 10-13 years and approximately 17%, 18%, 40%, and 25% were Tanner stage II, III, IV, and V, respectively.</p><p>LDL-C was reduced 38.3%, 44.6%, and 50.0% by rosuvastatin 5, 10 and 20 mg, respectively, compared to 0.7% for placebo.</p><p>At the end of the 40-week, open-label, titration to goal, dosing up to a maximum of 20 mg once daily, 70 of 173 patients (40.5%) had achieved the LDL-C goal of less than 2.8 mmol/l. After 52 weeks of study treatment, no effect on growth, weight, BMI or sexual maturation was detected (see Section 4.4). This trial (n=176) was not suited for comparison of rare adverse drug events.</p><p>Rosuvastatin was also studied in a 2-year open-label, titration-to-goal study in 198 children with heterozygous familial hypercholesterolaemia aged 6 to 17 years (88 male and 110 female, Tanner stage &lt;II-V). The starting dose for all patients was 5 mg rosuvastatin once daily. Patients aged 6 to 9 years (n=64) could titrate to a maximum dose of 10 mg once daily and patients aged 10 to 17 years (n=134) to a maximum dose of 20 mg once daily.</p><p>After 24 months of treatment with rosuvastatin, the LS mean percent reduction from the baseline value in LDL-C was -43% (Baseline: 236 mg/dL, Month 24: 133 mg/dL). For each age group, the LS mean percent reductions from baseline values in LDL-C were -43% (Baseline: 234 mg/dL, Month 24: 124 mg/dL), -45% (Baseline: 234 mg/dL, 124 mg/dL), and</p><p>-35% (Baseline: 241 mg/dL, Month 24: 153 mg/dL) in the 6 to &lt;10, 10 to &lt;14, and 14 to &lt;18 age groups, respectively.</p><p>Rosuvastatin 5 mg, 10 mg, and 20 mg also achieved statistically significant mean changes from baseline for the following secondary lipid and lipoprotein variables: HDL-C, TC, non- HDL-C, LDL-C/HDL-C, TC/HDL-C, TG/HDL-C, non-HDL-C/HDL-C, ApoB, ApoB/ApoA-</p><p>1. These changes were each in the direction of improved lipid responses and were sustained over 2 years.</p><p>No effect on growth, weight, BMI or sexual maturation was detected after 24 months of treatment (see Section 4.4).</p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with rosuvastatin in all subsets of the paediatric population in the treatment of homozygous familial hypercholesterolaemia, primary combined (mixed) dyslipidaemia and in the prevention of cardiovascular events (see Section 4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="text-align:justify"><strong>Absorption: </strong>Maximum rosuvastatin plasma concentrations are achieved approximately 5 hours after oral administration. The absolute bioavailability is approximately 20%.</p><p style="text-align:justify"><strong>Distribution</strong>: Rosuvastatin is taken up extensively by the liver which is the primary site of cholesterol synthesis and LDL-C clearance. The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.</p><p style="text-align:justify"><strong>Metabolism: </strong>Rosuvastatin&nbsp; undergoes&nbsp; limited&nbsp; metabolism&nbsp;&nbsp; (approximately&nbsp;&nbsp; 10%). <em>In vitro </em>metabolism studies using human hepatocytes indicate that rosuvastatin is a poor substrate for cytochrome P450-based metabolism. CYP2C9 was the principal isoenzyme involved, with 2C19, 3A4 and 2D6 involved to a lesser extent. The main metabolites identified are the N-desmethyl and lactone metabolites. The N-desmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive. Rosuvastatin accounts for greater than 90% of the circulating HMG-CoA reductase inhibitor activity.</p><p style="text-align:justify"><strong>Excretion: </strong>Approximately 90% of the rosuvastatin dose is excreted unchanged in the faeces (consisting of absorbed and non-absorbed active substance) and the remaining part is excreted in urine. Approximately 5% is excreted unchanged in urine. The plasma elimination half-life is approximately 19 hours. The elimination half-life does not increase at higher doses. The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%). As with other HMG-CoA reductase inhibitors, the hepatic uptake of rosuvastatin involves the membrane transporter OATP-C. This transporter is important in the hepatic elimination of rosuvastatin.</p><p style="text-align:justify"><strong>Linearity: </strong>Systemic exposure of rosuvastatin increases in proportion to dose. There are no changes in pharmacokinetic parameters following multiple daily doses.</p><p style="text-align:justify">Special populations:</p><p style="text-align:justify"><strong>Age and sex: </strong>There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin in adults. The exposure in children and adolescents with heterozygous familial hypercholesterolemia appears to be similar to or lower than that in adult patients with dyslipidaemia (see &ldquo;Paediatric population&rdquo; below).</p><p style="text-align:justify"><strong>Race: </strong>Pharmacokinetic studies show an approximate 2-fold elevation in&nbsp; median&nbsp; AUC&nbsp; and C<sub>max</sub> in Asian subjects (Japanese, Chinese, Filipino, Vietnamese and Koreans) compared with Caucasians; Asian-Indians show an approximate 1.3-fold elevation in&nbsp; median&nbsp; AUC&nbsp; and&nbsp; Cmax. A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.</p><p style="text-align:justify"><strong>Renal insufficiency: </strong>In a study in subjects with varying degrees of renal impairment, mild to moderate renal disease had no influence on plasma concentration of rosuvastatin or the N- desmethyl metabolite. Subjects with severe impairment (CrCl &lt;30 ml/min) had a 3-fold increase in plasma concentration and a 9-fold increase in the N-desmethyl metabolite</p><p style="text-align:justify">&nbsp;</p><p style="text-align:justify">concentration compared to healthy volunteers. Steady-state plasma concentrations of rosuvastatin in subjects undergoing haemodialysis were approximately 50% greater compared to healthy volunteers.</p><p style="text-align:justify"><strong>Hepatic insufficiency: </strong>In a study with subjects with varying degrees of hepatic impairment there was no evidence of increased exposure to rosuvastatin in subjects with Child-Pugh scores of 7 or below. However, two subjects with Child-Pugh scores of 8 and 9 showed an increase in systemic exposure of at least 2-fold compared to subjects with lower Child-Pugh scores. There is no experience in subjects with Child-Pugh scores above 9.</p><p style="text-align:justify"><strong>Genetic polymorphisms: </strong>Disposition of HMG-CoA reductase inhibitors, including rosuvastatin, involves OATP1B1 and BCRP transporter proteins. In patients with SLCO1B1 (OATP1B1) and/or ABCG2 (BCRP) genetic polymorphisms there is a risk of increased rosuvastatin exposure. Individual polymorphisms of SLCO1B1 c.521CC and ABCG2 c.421AA are associated with a higher rosuvastatin exposure (AUC) compared to the SLCO1B1 c.521TT or ABCG2 c.421CC genotypes. This specific genotyping is not established in clinical practice, but for patients who are known to have these types of polymorphisms, a lower daily dose of Zyrosa is recommended.</p><p style="text-align:justify"><strong>Paediatric population: </strong>Two pharmacokinetic studies with rosuvastatin (given as tablets) in paediatric patients with heterozygous familial hypercholesterolaemia 10-17 or 6-17 years of age (total of 214 patients) demonstrated that exposure in paediatric patients appears comparable to or lower than that in adult patients. Rosuvastatin exposure was predictable with respect to dose and time over a 2-year period.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, genotoxicity and carcinogenicity potential. Specific tests for effects on hERG have not been evaluated. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels were as follows: In repeated- dose toxicity studies histopathologic liver changes likely due to the pharmacologic action of rosuvastatin were observed in mouse, rat, and to a lesser extent with effects in the gall bladder in dogs, but not in monkeys. In addition, testicular toxicity was observed in monkeys and dogs at higher dosages. Reproductive toxicity was evident in rats, with reduced litter sizes, litter weight and pup survival observed at maternally toxic doses, where systemic exposures were several times above the therapeutic exposure level.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, microcrystalline cellulose, crospovidone, tribasic calcium phosphate, magnesium stearate, opadry pink 02F84852 and purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>Protect from light &amp; moisture</p><p>Keep out of reach of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Alu/Alu blister packs of 2 x 14&rsquo;s tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                OMAN PHARMACEUTICAL PRODUCTS .CO. L.L.C., Salalah, Sultanate of Oman.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                October 2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>